fda ends semaglutide Ozempic picks up indication to treat chronic kidney disease FDA Warns on Certain Forms

The absolute risk increase for diabetic retinopathy complications was greater among patients with a history of diabetic retinopathy at baseline (semaglutide 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide 0.7%, placebo 0.4%)

B.et al (2010)

NP (after a provisional period)

Similar to findings in male mice, vehicle-treated Glp1r fl/fl and Glp1r Wnt1/ mice showed weight gain or maintenance of body weight, changing by 4.6% and 0.4%, respectively, over the course of treatment

Does obesity produce a distinct asthma phenotype

Before we change anything, we ask what else is going on